Developmental disease and cancer: Biological and clinical overlaps

American Journal of Medical Genetics, Part A

Volumn 161, Issue 11, 2013, Pages 2788-2796

  Bellacosa, Alfonso ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Cancer; Development

Indexed keywords

COHESIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN;

AKT GENE; APOPTOSIS; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; CANCER SUSCEPTIBILITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOME DAMAGE; COHESINOPATHY; DEVELOPMENTAL DISORDER; EPIGENETICS; FAMILIAL CANCER; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC DISORDER; GENOMIC INSTABILITY; HUMAN; MEK ERK GENE; MULTIPLE CANCER; NEOPLASM; ONCOGENE RAS; PHAKOMATOSIS; PI3K GENE; PRIORITY JOURNAL; PROTEIN DEFECT; PTEN GENE; RAF GENE; RASOPATHY; RECESSIVE CHROMOSOME BREAKAGE SYNDROME; RECESSIVE GENE; RETINA INJURY; SEGMENTAL OVERGROWTH LIPOMATOSIS ARTERIOVENOUS MALFORMATION AND EPIDERMAL NEVUS; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR GENE;

CANCER; DEVELOPMENT;

DEVELOPMENTAL DISABILITIES; EPIGENESIS, GENETIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; PHENOTYPE;

EID: 84886294284     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.36267     Document Type: Article

References (54)

1. Baylin S. 2009. Stem cells, cancer, and epigenetics. In: Stem Book (Internet). Cambridge, MA: Harvard Stem Cell Institute.
2. Bellacosa A, Chan TO, Ahmed NN, Datta K, Malstrom S, Stokoe D, McCormick F, Feng J, Tsichlis P. 1998. Akt activation by growth factors is a multiple-step process: The role of the PH domain. Oncogene 17:313-325.
3. Bellacosa A, Godwin AK, Peri S, Devarajan K, Caretti E, Vanderveer L, Bove B, Slater C, Zhou Y, Daly M, Howard S, Campbell KS, Nicolas E, Yeung AT, Clapper ML, Crowell JA, Lynch HT, Ross E, Kopelovich L, Knudson AG. 2010. Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations. Cancer Prev Res 3:48-61.
4. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. 2005. Activation of AKT kinases in cancer: Implications for therapeutic targeting. Adv Cancer Res 94:29-86.
5. Biesecker LG, Sapp JC. 1993. Proteus syndrome. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Stephens K, editors. GeneReviews. Seattle, WA: University of Washington, Seattle.
6. Bose T, Gerton JL. 2010. Cohesinopathies, gene expression, and chromatin organization. J Cell Biol 189:201-210.
7. Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G. 2013. BAP1 and cancer. Nat Rev Cancer 13:153-159.
8. Caux F, Plauchu H, Chibon F, Faivre L, Fain O, Vabres P, Bonnet F, Selma ZB, Laroche L, Gerard M, Longy M. 2007. Segmental overgrowth, lipomatosis, arteriovenous malformation and epidermal nevus (SOLAMEN) syndrome is related to mosaic PTEN nullizygosity. Eur J Hum Genet 15:767-773.
9. Choufani S, Shuman C, Weksberg R. 2013. Molecular findings in Beckwith-Wiedemann syndrome. Am J Med Genet Part C Semin Med Genet 163C:131-140.
10. Chudasama KK, Winnay J, Johansson S, Claudi T, Konig R, Haldorsen I, Johansson B, Woo JR, Aarskog D, Sagen JV, Kahn CR, Molven A, Njolstad PR. 2013. SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling. Am J Hum Genet 93:150-157.
11. Dey A, Seshasayee D, Noubade R, French DM, Liu J, Chaurushiya MS, Kirkpatrick DS, Pham VC, Lill JR, Bakalarski CE, Wu J, Phu L, Katavolos P, LaFave LM, Abdel-Wahab O, Modrusan Z, Seshagiri S, Dong K, Lin Z, Balazs M, Suriben R, Newton K, Hymowitz S, Garcia-Manero G, Martin F, Levine RL, Dixit VM. 2012. Loss of the tumor suppressor BAP1 causes myeloid transformation. Science 337:1541-1546.
12. Dyment DA, Smith AC, Alcantara D, Schwartzentruber JA, Basel-Vanagaite L, Curry CJ, Temple IK, Reardon W, Mansour S, Haq MR, Gilbert R, Lehmann OJ, Vanstone MR, Beaulieu CL, Majewski J, Bulman DE, O'Driscoll M, Boycott KM, Innes AM. 2013. Mutations in PIK3R1 cause SHORT syndrome. Am J Hum Genet 93:158-166.
13. Economides KD, Capecchi MR. 2003. Hoxb13 is required for normal differentiation and secretory function of the ventral prostate. Development 130:2061-2069.
14. Economides KD, Zeltser L, Capecchi MR. 2003. Hoxb13 mutations cause overgrowth of caudal spinal cord and tail vertebrae. Dev Biol 256:317-330.
15. Eng C. 2003. PTEN: One gene, many syndromes. Hum Mutat 22:183-198.
16. Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, Wiley KE, Isaacs SD, Johng D, Wang Y, Bizon C, Yan G, Gielzak M, Partin AW, Shanmugam V, Izatt T, Sinari S, Craig DW, Zheng SL, Walsh PC, Montie JE, Xu J, Carpten JD, Isaacs WB, Cooney KA. 2012. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 366:141-149.
17. Farley MN, Schmidt LS, Mester JL, Pena-Llopis S, Pavia-Jimenez A, Christie A, Vocke CD, Ricketts CJ, Peterson J, Middelton L, Kinch L, Grishin N, Merino MJ, Metwalli AR, Xing C, Xie XJ, Dahia PL, Eng C, Linehan WM, Brugarolas J. 2013. Germline BAP1 mutation predisposes to familial clear-cell renal cell carcinoma. Mol Cancer Res 11:1061-1071.
18. Ganmore I, Smooha G, Izraeli S. 2009. Constitutional aneuploidy and cancer predisposition. Hum Mol Genet 18:R84-R93.
19. George S, Rochford JJ, Wolfrum C, Gray SL, Schinner S, Wilson JC, Soos MA, Murgatroyd PR, Williams RM, Acerini CL, Dunger DB, Barford D, Umpleby AM, Wareham NJ, Davies HA, Schafer AJ, Stoffel M, O'Rahilly S, Barroso I. 2004. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science 304:1325-1328.
20. Happle R. 2007. Type 2 segmental Cowden disease vs. Proteus syndrome. Br J Dermatol 156:1089-1090.
21. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ, Wang ZY. 1988. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567-572.
22. Hussain K, Challis B, Rocha N, Payne F, Minic M, Thompson A, Daly A, Scott C, Harris J, Smillie BJ, Savage DB, Ramaswami U, De Lonlay P, O'Rahilly S, Barroso I, Semple RK. 2011. An activating mutation of AKT2 and human hypoglycemia. Science 334:474.
23. Kinzler KW, Vogelstein B. 1997. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386:761-763.
24. Kline AD, Grados M, Sponseller P, Levy HP, Blagowidow N, Schoedel C, Rampolla J, Clemens DK, Krantz I, Kimball A, Pichard C, Tuchman D. 2007. Natural history of aging in Cornelia de Lange syndrome. Am J Med Genet Part C 145C:248-260.
25. Knudson AG. 1971. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820-823.
26. Knudson AG. 2001. Two genetic hits (more or less) to cancer. Nat Rev Cancer 1:157-162.
27. Kratz CP, Rapisuwon S, Reed H, Hasle H, Rosenberg PS. 2011. Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. Am J Med Genet Part C 157C:83-89.
28. Lim KC, Lakshmanan G, Crawford SE, Gu Y, Grosveld F, Engel JD. 2000. Gata3 loss leads to embryonic lethality due to noradrenaline deficiency of the sympathetic nervous system. Nat Genet 25:209-212.
29. Lindhurst MJ, Parker VE, Payne F, Sapp JC, Rudge S, Harris J, Witkowski AM, Zhang Q, Groeneveld MP, Scott CE, Daly A, Huson SM, Tosi LL, Cunningham ML, Darling TN, Geer J, Gucev Z, Sutton VR, Tziotzios C, Dixon AK, Helliwell T, O'Rahilly S, Savage DB, Wakelam MJ, Barroso I, Biesecker LG, Semple RK. 2012. Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. Nat Genet 44:928-933.
30. Lindhurst MJ, Sapp JC, Teer JK, Johnston JJ, Finn EM, Peters K, Turner J, Cannons JL, Bick D, Blakemore L, Blumhorst C, Brockmann K, Calder P, Cherman N, Deardorff MA, Everman DB, Golas G, Greenstein RM, Kato BM, Keppler-Noreuil KM, Kuznetsov SA, Miyamoto RT, Newman K, Ng D, O'Brien K, Rothenberg S, Schwartzentruber DJ, Singhal V, Tirabosco R, Upton J, Wientroub S, Zackai EH, Hoag K, Whitewood-Neal T, Robey PG, Schwartzberg PL, Darling TN, Tosi LL, Mullikin JC, Biesecker LG. 2011. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med 365:611-619.
31. Mannini L, Menga S, Musio A. 2010. The expanding universe of cohesin functions: A new genome stability caretaker involved in human disease and cancer. Hum Mutat 31:623-630.
32. Marsh DJ, Trahair TN, Kirk EP. 2011. Mutant AKT1 in Proteus syndrome. N Engl J Med 365:2141-2142; author reply 2142.
33. Marsh DJ, Trahair TN, Martin JL, Chee WY, Walker J, Kirk EP, Baxter RC, Marshall GM. 2008. Rapamycin treatment for a child with germline PTEN mutation. Nat Clin Pract Oncol 5:357-361.
34. Mintz B. 1971. Clonal basis of mammalian differentiation. Symp Soc Exp Biol 25:345-370.
35. Mintz B. 1978. Gene expression in neoplasia and differentiation. Harvey Lect 71:193-246.
36. Opitz JM, Jorde LB. 2011. Hamartoma syndromes, exome sequencing, and a protean puzzle. N Engl J Med 365:661-663.
37. Poduri A, Evrony GD, Cai X, Elhosary PC, Beroukhim R, Lehtinen MK, Hills LB, Heinzen EL, Hill A, Hill RS, Barry BJ, Bourgeois BF, Riviello JJ, Barkovich AJ, Black PM, Ligon KL, Walsh CA. 2012. Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron 74:41-48.
38. Pollak M. 2008. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915-928.
39. Ponder BA. 2001. Cancer genetics. Nature 411:336-341.
40. Riviere JB, Mirzaa GM, O'Roak BJ, Beddaoui M, Alcantara D, Conway RL, St-Onge J, Schwartzentruber JA, Gripp KW, Nikkel SM, Worthylake T, Sullivan CT, Ward TR, Butler HE, Kramer NA, Albrecht B, Armour CM, Armstrong L, Caluseriu O, Cytrynbaum C, Drolet BA, Innes AM, Lauzon JL, Lin AE, Mancini GM, Meschino WS, Reggin JD, Saggar AK, Lerman-Sagie T, Uyanik G, Weksberg R, Zirn B, Beaulieu CL, Majewski J, Bulman DE, O'Driscoll M, Shendure J, Graham JM, Jr. Boycott KM, Dobyns WB. 2012. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat Genet 44:934-940.
41. Russo J, Lynch HT, Russo IH. 2001. Mammary gland architecture as a determining factor in the susceptibility of the human breast to cancer. Breast J 7:278-291.
42. Salazar H, Godwin AK, Daly MB, Laub PB, Hogan WM, Rosenblum N, Boente MP, Lynch HT, Hamilton TC. 1996. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 88:1810-1820.
43. Schubbert S, Shannon K, Bollag G. 2007. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7:295-308.
44. Tartaglia M, Gelb BD. 2010. Disorders of dysregulated signal traffic through the RAS-MAPK pathway: Phenotypic spectrum and molecular mechanisms. Ann N Y Acad Sci 1214:99-121.
45. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, Hesdorffer M, Nasu M, Powers A, Rivera Z, Comertpay S, Tanji M, Gaudino G, Yang H, Carbone M. 2011. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43:1022-1025.
46. Testa JR, Malkin D, Schiffman JD. 2013. Connecting molecular pathways to hereditary cancer risk syndromes. Am Soc Clin Oncol Educ Book 2013 2013:81-90.
47. Thauvin-Robinet C, Auclair M, Duplomb L, Caron-Debarle M, Avila M, St-Onge J, Le Merrer M, Le Luyer B, Heron D, Mathieu-Dramard M, Bitoun P, Petit JM, Odent S, Amiel J, Picot D, Carmignac V, Thevenon J, Callier P, Laville M, Reznik Y, Fagour C, Nunes ML, Capeau J, Lascols O, Huet F, Faivre L, Vigouroux C, Riviere JB. 2013. PIK3R1 mutations cause syndromic insulin resistance with lipoatrophy. Am J Hum Genet 93:141-149.
48. Tidyman WE, Rauen KA. 2009. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev 19:230-236.
49. Truchuelo T, Diaz-Ley B, Rios L, Alcantara J, Jaen P. 2012. Facial angiofibromas treated with topical rapamycin: An excellent choice with fast response. Dermatol Online J 18:15.
50. Vilenchik MM, Knudson AG. 2003. Endogenous DNA double-strand breaks: Production, fidelity of repair, and induction of cancer. Proc Natl Acad Sci USA 100:12871-12876.
51. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, Weisenberger DJ, Campan M, Young J, Jacobs I, Laird PW. 2007. Epigenetic stem cell signature in cancer. Nat Genet 39:157-158.
52. Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, Windpassinger C, Wackernagel W, Loy S, Wolf I, Viale A, Lash AE, Pirun M, Socci ND, Rutten A, Palmedo G, Abramson D, Offit K, Ott A, Becker JC, Cerroni L, Kutzner H, Bastian BC, Speicher MR. 2011. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 43:1018-1021.
53. Wimmer K, Etzler J. 2008. Constitutional mismatch repair-deficiency syndrome: Have we so far seen only the tip of an iceberg? Hum Genet 124:105-122.
54. Xiong B, Gerton JL. 2010. Regulators of the cohesin network. Annu Rev Biochem 79:131-153.